Single-stranded oligonucleotide probes for chromosome or gene copy enumeration

Patent metadata

Field	Value
Publication number	US-11788149-B2
Application number	US-202016879228-A
Country	US
Kind code	B2
Filing date	May 20, 2020
Priority date	Feb 21, 2014
Publication date	Oct 17, 2023
Grant date	Oct 17, 2023

Abstract

Single-stranded oligonucleotide probes, systems, kits and methods for chromosome enumeration, gene copy enumeration, or tissue diagnostics. The probes are particularly suited for detecting gene amplification, deletion, or rearrangement in tissue samples in a single, dual, or multiplexed assay. The probes exhibit improved performance compared to industry leading dual-stranded probes; particularly in terms of the rate of hybridization.

First claim

The invention claimed is:

1. A system for in situ detection of a control region of human chromosome 17, said system comprising:
a set of two or more single-stranded control probes specific for X distinct monomers of an alpha satellite control region of human chromosome 17, wherein X=2-14, the control probes are each labeled with at least one first label, wherein the control probes, when applied to a sample, are configured to achieve at least two enumerable signals per cell with a staining intensity of ≥2 and staining coverage of ≥50% of the number of total nuclei within 3 hours of hybridization.

2. A system for in situ detection of a control region of human chromosome 17, said system comprising:
a set of two or more single-stranded control probes specific for X distinct monomers of an alpha satellite control region of human chromosome 17, wherein X=2-14, the control probes are each labeled with at least one first label, wherein the control probes can achieve an enumerable signal when hybridized to chromosome 17, each enumerable signal having a generally round shape, wherein a round shape is a shape defined by a simple closed curve fitting within a first region, the first region being an area on and between an inner concentric circle and an outer concentric circle, the inner concentric circle having an inner radius (R in ) and the outer concentric circle having an outer radius (R out ) wherein R in is ≥ 50% of R out , and the simple closed curve having a radius R simple , wherein R in ≤ R simple ≤ R out , and wherein the simple closed curve is a connected curve that does not cross itself and ends at the same point where it begins.

3. The system of claim 1 , wherein each probe comprises:
a sequence selected from the group consisting of SEQ ID NOs: 3-16; or
a sequence selected from the group consisting of a truncated version of SEQ ID NOs: 3-16, the truncated version being at least 40 contiguous bp of said SEQ ID NOs:3-16; or
a sequence selected from the group consisting of a sequence that has at least 70% sequence identity to one of SEQ ID NOs: 3-16, or
complements thereof.

4. The system of claim 1 , further comprising a target probe specific to a target region of human chromosome 17, wherein the target probe is labeled with at least one second label.

5. The system of claim 4 , wherein the target probe is specific to a target region near or around the HER2 gene locus.

6. The system of claim 4 , wherein the target probe is specific to a region between nucleotides 35,027,979 and 35,355,516 of human chromosome 17.

7. A probe for use in a bright-field chromogenic in situ hybridization, the probe comprising a set of two or more single-stranded control probes specific for X distinct monomers of an alpha satellite control region of chromosome 17, wherein X=2-14, wherein the control probes are each labeled with at least one first label, wherein each control probe has a length from 40 to 120 nucleotides, and wherein the control probes are selected so as to not evidently bind non-specifically in the absence of blocking DNA.

8. A probe comprising a plurality of single-stranded oligonucleotide control probes, each control probe comprising:
a sequence selected from the group consisting of SEQ ID NOs: 3-16; or a sequence selected from the group consisting of a truncated version of SEQ ID NOs: 3-16, the truncated version being at least 40 contiguous bp of said SEQ ID NOs:3-16; or
a sequence selected from the group-consisting of a sequence that has at least 70% sequence identity to one of SEQ ID NOs: 3-16; and
wherein each control probe has a length from 40 to 120 nucleotides.

9. The system of claim 2 , wherein each probe comprises:
a sequence selected from the group consisting of SEQ ID NOs: 3-16; or
a sequence selected from the group consisting of a truncated version of SEQ ID NOs: 3-16, the truncated version being at least 40 contiguous bp of said SEQ ID NOs:3-16; or
a sequence selected from the group consisting of a sequence that has at least 70% sequence identity to one of SEQ ID NOs: 3-16, or
complements thereof.

10. The system of claim 2 , further comprising a target probe specific to a target region of human chromosome 17, wherein the target probe is labeled with at least one second label.

11. The system of claim 10 , wherein the target probe is specific to a target region near or around the HER2 gene locus.

12. The system of claim 10 , wherein the target probe is specific to a region between nucleotides 35,027,979 and 35,355,516 of human chromosome 17.

Assignees

• Ventana Med Syst Inc

Inventors

• Farrell Michael
• Hubbard Antony
• Johnson Donald
• Kelly Brian
• Shingler Taylor
• Tang Lei
• Zhang Wenjun

Classifications

• C12Q1/6886 Primary

  for cancer (immunoassay for cancer G01N33/575) · CPC title

• C12Q1/6841 Primary

  In situ hybridisation · CPC title

• C12Q2600/156

  Polymorphic or mutational markers · CPC title

• C12Q2600/158

  Expression markers · CPC title

• C12Q2537/143

  Multiplexing, i.e. use of multiple primers or probes in a single reaction, usually for simultaneously analyse of multiple analysis · CPC title